Business Wire

SoftBank Corp. and Intelsat Launch Landmark Collaboration to Create Ubiquitous Network

17.9.2024 02:00:00 CEST | Business Wire | Press release

Share

SoftBank Corp. (“SoftBank”) and Intelsat signed a groundbreaking collaboration agreement that will lead to the launch of a single “Ubiquitous Network” enabling customers to stay connected everywhere they go. SoftBank and Intelsat will jointly lead research and development of seamless 5G connections between terrestrial mobile networks and satellite communications networks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916589802/en/

In a society where everyone and everything is increasingly dependent on staying connected, convenient, and always-on, telecommunications are essential. However, despite the coming realization of autonomous mobility with automobiles, ships, drones and other vehicles, many areas are still without ground-based mobile network coverage and require separate devices and accounts to connect to non-terrestrial networks.

Through the new collaboration, SoftBank and Intelsat plan to jointly develop a hybrid communication solution that allows users to stay connected via available networks, whether terrestrial or satellite, anywhere in the world with the convenience of one device and one account. The solution will build on the same standard architectures, interfaces and processes that enable roaming of devices between terrestrial cellular networks today and will help make the commercial adoption of mobility solutions based on new 3GPP 5G standards for non-terrestrial networks a reality much sooner.

One of the key goals of the collaboration is to develop a universal device that will always stay connected regardless of where in the world it goes. For example, a future connected vehicle equipped with such a device will be able to seamlessly switch to a non-terrestrial satellite communication network when outside of terrestrial mobile network coverage. The targeted solution is expected to have wide commercial applicability, including in land mobile, maritime, and disaster response and recovery.

Design, development, field testing and commercialization of new hybrid network products between Intelsat and SoftBank will be conducted in phases, aligned with the development of the new 3GPP 5G non-terrestrial network standards. The resulting hybrid solutions will allow for existing satellite terminals to be used in the near term and newer 5G-based terminals as they become available.

“Intelsat and SoftBank share a pioneering vision of Ubiquitous Networking and seamless interoperability between satellite and terrestrial networks,” said Bruno Fromont, Intelsat Chief Technology Officer. “Until now, the challenge was aligning standards that allowed the two different networks to connect. With recent progress on 5G-based standardization of non-terrestrial networks led by Intelsat at 3GPP and this strategic collaboration with SoftBank, we are ideally positioned to accelerate the design and practical implementation of commercial hybrid services that will allow devices to freely roam between satellite and terrestrial networks.”

Hideyuki Tsukuda, Executive Vice President and CTO of SoftBank said, "By using technology that switches between terrestrial mobile networks and satellite communication networks through roaming, we can integrate the two previously separate networks and utilize satellite communication as an extension of mobile communication. Through this joint research and development, SoftBank and Intelsat will aim to build a Ubiquitous Network where people and things around the world can be connected to communication anytime, anywhere."

About Intelsat

Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.

About SoftBank Corp.

Guided by the SoftBank Group’s corporate philosophy, “Information Revolution – Happiness for everyone,” SoftBank Corp. (TOKYO: 9434) operates telecommunications and IT businesses in Japan and globally. In the fiscal year ended March 2024, SoftBank Corp. registered 6,084.0 billion yen of revenue, 876.1 billion yen of operating income and 489.1 billion yen of net income. SoftBank Corp. has 40 million mobile subscribers in Japan, and through its group companies, 63 million smartphone payment (PayPay) users, 85 million online media (Yahoo! JAPAN) users and 97 million communication app (LINE) users (as of May 9, 2024). Building on its strong business foundation, SoftBank Corp. is expanding into non-telecom fields in line with its “Beyond Carrier” growth strategy while further growing its telecom business by harnessing the power of 5G/6G, IoT, Digital Twin and Non-Terrestrial Network (NTN) solutions, including High Altitude Platform Station (HAPS)-based stratospheric telecommunications. While constructing AI data centers and developing homegrown LLMs specialized for the Japanese language with 1 trillion parameters, SoftBank is applying AI to enhance radio access network performance (AI-RAN) with the aim of becoming a provider of next-generation social infrastructure. In recognition of its ESG initiatives, SoftBank Corp. was selected for inclusion in the Dow Jones Sustainability World Index (DJSI World) for 2022 and 2023, achieving the highest score in Japan and registering as the only company in the country to be selected for the Telecommunication Services industry group in 2023. To learn more, please visit https://www.softbank.jp/en/.

Follow Us on Social Media:
Twitter/X: https://twitter.com/INTELSAT
LinkedIn: https://www.linkedin.com/company/intelsat
Instagram: https://www.instagram.com/intelsat/?hl=en
YouTube: https://www.youtube.com/user/intelsatmedia

View source version on businesswire.com: https://www.businesswire.com/news/home/20240916589802/en/

Contacts

Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881

Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye